当前位置:首页 >财报库 > 报告详情

默沙东Merck & Co. Inc.(MRK)2024年10-K年度报告「NYSE」(英文版)(395页).pdf

上传人: Kell****reet 编号:652448 2025-05-14 395页 10.39MB

下载:

1、As filed with the Securities and Exchange Commission on February 25,2025UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549_FORM 10-K Annual Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934For the Fiscal Year Ended December 31,2024ORTransition Report Pursu

2、ant to Section 13 or 15(d)of the Securities Exchange Act of 1934For the transition period from to Commission File No.1-6571Merck&Co.,Inc.126 East Lincoln AvenueRahwayNew Jersey07065(908)740-4000New Jersey22-1918501(State or other jurisdiction of incorporation)(I.R.S.Employer Identification No.)Secur

3、ities Registered pursuant to Section 12(b)of the Act:Title of Each ClassTrading Symbol(s)Name of Each Exchange on which RegisteredCommon Stock($0.50 par value)MRKNew York Stock Exchange1.875%Notes due 2026MRK/26New York Stock Exchange3.250%Notes due 2032MRK/32New York Stock Exchange2.500%Notes due 2

4、034MRK/34New York Stock Exchange1.375%Notes due 2036MRK 36ANew York Stock Exchange3.500%Notes due 2037MRK/37New York Stock Exchange3.700%Notes due 2044MRK/44New York Stock Exchange3.750%Notes due 2054MRK/54New York Stock ExchangeSecurities Registered pursuant to Section 12(g)of the Act:NoneIndicate

5、by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has fi

6、led all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorterperiod that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要介绍了Merck & Co., Inc.(Merck或公司)的业务概况、竞争环境、监管环境以及药物可获得性。 1. Merck是一家全球性医疗保健公司,通过其处方药、疫苗和动物健康产品提供创新的健康解决方案。 2. Merck面临来自其他全球性制药公司、小型研究公司、仿制药制造商和动物保健公司的激烈竞争。 3. 该公司在定价和市场准入方面面临全球范围内的压力,特别是在美国、欧盟、日本和中国等关键市场。 4. Merck的产品开发和销售受到严格的监管,包括美国食品药品监督管理局(FDA)和欧盟的监管。 5. Merck致力于确保其科学成果推动医疗保健进步,并使产品在全球范围内可获得和负担得起。 6. Merck通过与各种利益相关者合作,设计和提供可持续的获取解决方案,以解决支付者、提供者和患者层面的障碍。
默克公司面临哪些主要竞争压力? 默克公司如何应对全球医疗保健成本控制压力? 默克公司如何确保其产品在全球范围内可获得性和可负担性?
客服
商务合作
小程序
服务号
折叠